Current insights: a systemic review of therapeutic options for peanut allergy.
Current insights: a systemic review of therapeutic options for peanut allergy.
复制标题
DOI：
10.1097/aci.0000000000000824
复制
发表时间：
2022-06-01
影响因子：
2.8
通讯作者：
中科院分区：
文献类型：
--
作者：
随着花生过敏（PA）在全球范围内的流行，以及由于坚果在食品中的主导作用而发生潜在反应的风险增加，PA在过去十年中已成为一个重要的公共卫生问题，影响了多达500万美国成年人口。本综述详细介绍了过去一年中发生的患病率，诊断和免疫治疗的更新和进展。治疗和诊断的进展仍然处于研究的最前沿，并继续推动食物过敏（FA）领域向前发展，为PA的检测和治疗提供了有前途的作用。FA领域在花生免疫治疗、生物标志物诊断和生活质量改善方面取得了重大进展。考虑到PA患者的负担和后果，临床实践中的这些进展可以显着改善PA患者及其护理人员的生活质量。正在进行的研究将继续调查脱敏的长期结果措施和针对家庭需求的有效管理计划。
With increasing prevalence of Peanut Allergy (PA) globally and the greater risk of potential reactions occurring due to the leading role of nuts in food products, PA has become a significant public health concern over the past decade, affecting up to 5 million of the US adult population. This review details updates and advances in prevalence, diagnosis, and immunotherapies that have occurred over the past year. Therapeutic and diagnostic advances remain at the forefront of research and have continued to push the Food Allergy (FA) field forward to provide a promising role in the detection and treatment of PA. The FA field has researched significant advances in peanut immunotherapy, biomarker diagnosis, and quality of life improvement. Given the burden and consequences for individuals with PA, these advances delivered in clinical practice can significantly improve the quality of life of individuals with PA and their caregivers. Ongoing studies will continue to investigate long-term outcome measures of desensitisation and effective management plans tailored to the families’ needs.